Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia

ISSN： 1357-0560

Source： Medical Oncology, Vol.28, Iss.2, 2011-06, pp. : 532-538

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alemtuzumab in chronic lymphocytic leukemia

By James Danelle F Kipps Thomas J

Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. : 29-42

Future Medicine

Access to resources Recommend Favorite

Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia

By Lundin Jeanette Karlsson Claes Celsing Fredrik

Medical Oncology, Vol. 23, Iss. 1, 2006-03 ,pp. : 137-139

Humana Press, Inc

Access to resources Recommend Favorite

Chronic lymphocytic leukemia

By Andritsos Leslie Khoury Hanna

Current Treatment Options in Oncology, Vol. 3, Iss. 3, 2002-06 ,pp. : 225-231

Springer Publishing Company

Access to resources Recommend Favorite

Symptomatic BK virus reactivation following fludarabine, cyclophosphamide and rituximab chemotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma

By Appleby Niamh Dillon Anna Arrigan Martin Fennell Jerome Crowley Brendan Hayden Patrick J. Enright Helen

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1181-1183

Informa Healthcare

Access to resources Recommend Favorite

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina Ösby Eva Lundin Jeanette Kalin Mats Österborg Anders Gruber Astrid

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite